Trial reportHelicobacter
14-Day Vonoprazan-Minocycline Dual Therapy Versus Bismuth-Containing Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Single-Center Randomized Controlled Noninferiority Trial.
Trial report in Helicobacter. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundRescue treatment for Helicobacter pylori infection remains challenging in regions with high antibiotic resistance. Although bismuth-containing quadruple therapy is widely recommended as an empirical rescue regimen, its medication burden may impair tolerability and adherence. This trial evaluated the efficacy and safety of 14-day vonoprazan-minocycline dual therapy compared with vonoprazan-based bismuth-containing quadruple therapy as empirical rescue treatment. MATERIALS AND
methodsThis single-center, prospective, open-label, randomized, controlled, noninferiority trial enrolled 186 adults aged 18-70 years with at least one previous H. pylori eradication failure. Patients were randomly assigned (1:1) to receive 14-day vonoprazan-minocycline dual therapy or vonoprazan-, amoxicillin-, minocycline-, and bismuth-containing quadruple therapy. Eradication was assessed by a
resultsEradication rates in the dual therapy and quadruple therapy groups were 89.2% and 91.4% in the ITT analysis (difference, -2.2%; 95% CI, -10.5% to 6.2%; noninferiority p = 0.036), 90.2% and 92.4% in the mITT analysis (difference, -2.2%; 95% CI, -9.7% to 5.3%; noninferiority p = 0.030), and 91.2% and 93.4% in the PP analysis (difference, -2.2%; 95% CI, -9.4% to 5.0%; noninferiority p = 0.024). Noninferiority was demonstrated in the mITT and PP analyses, whereas the ITT result should be interpreted cautiously because the lower 95% CI bound crossed the margin. Adverse events were similar between treatment groups (11.8% vs. 15.1%; χ
conclusions14-day vonoprazan-minocycline dual therapy achieved eradication rates comparable to those of bismuth-containing quadruple therapy, with acceptable safety and high adherence as rescue treatment for H. pylori infection. This simplified regimen may be considered a potential empirical rescue option when susceptibility testing is not readily available, although the ITT noninferiority result warrants cautious interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.